Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
IntelGenx Technologies (IGXT)
OTHER OTC:IGXT
Holding IGXT?
Track your performance easily
Earnings Data
Report Date
Mar 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: 0.00%
|Next Earnings Date:Mar 20, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in revenue growth and strategic partnerships, particularly in pharmaceuticals and animal health. However, challenges remain with product launches in Europe and FDA approvals. Overall, the company is optimistic about upcoming milestones and revenue streams.Company Guidance
During the IntelGenx Q4 2023 earnings call, several key metrics and guidance were provided for the upcoming year. The company reported a significant increase in Q4 revenue to $426,000, marking a 146% growth compared to the previous year, primarily driven by increased R&D revenue. Total revenue for the year reached $1.039 million, with operating costs at $10.5 million, leading to a net comprehensive loss of $10.1 million, an improvement from the $11.5 million loss in 2022. The company anticipates a phase of rapid growth with the upcoming U.S. launch of RIZAFILM in Q2 2024 and plans to support this growth through a Reg A offering aimed at raising up to $20 million. They are also focused on finding a new commercial partner for RIZAPORT in Europe and advancing several clinical trials, including those for Montelukast VersaFilm in Alzheimer's and Parkinson's diseases. Additionally, IntelGenx is exploring expansion in its CDMO business model with expectations to initiate 3 to 5 new development projects in 2024.Record Revenue Growth in Q4 2023
Total revenue for the fourth quarter increased by 146% to $426,000 compared to $173,000 for the same period last year.
First Purchase Order for RIZAFILM
Received first purchase order for RIZAFILM from Gensco Pharma, marking a significant milestone.
Settlement Agreement with Tilray
Entered into a settlement agreement with Tilray, including a purchase order for three new products.
Animal Health Advancements
Development and licensing agreements signed with Covenant Animal Health, potentially opening new commercial opportunities.
Montelukast Clinical Trials Progress
Completed dosing in Montelukast VersaFilm IIa trial; Phase II trial in Parkinson's disease to begin dosing soon.
---
IGXT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IGXT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $0.17 | $0.17 | 0.00% |
| Aug 08, 2024 | $0.17 | $0.17 | 0.00% |
| May 09, 2024 | $0.16 | $0.17 | +6.25% |
| Mar 21, 2024 | $0.16 | $0.16 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does IntelGenx Technologies (IGXT) report earnings?
IntelGenx Technologies (IGXT) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
What is IntelGenx Technologies (IGXT) earnings time?
IntelGenx Technologies (IGXT) earnings time is at Mar 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IGXT EPS forecast?
Currently, no data Available
---